Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192.SS) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · China · ISIN CNE1000055W8
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 359.90 m CNY | 801.14 m CNY |
| Gross profit | 350.58 m CNY | 766.91 m CNY |
| Operating income | -932.84 m CNY | -760.33 m CNY |
| EBIT | -916.90 m CNY | -735.91 m CNY |
| Net income | -845.96 m CNY | -764.05 m CNY |
| Diluted EPS – continuing operations | -2.03 CNY | -1.66 CNY |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Dizal (Jiangsu) Pharmaceutical Co. Ltd. A
Dizal (Jiangsu) Pharmaceutical Co., Ltd., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of oncology and hematologic disorders. Its assets include the ZEGFROVY, for the treatment of solid tumors; Gao Ruizhe to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and solid tumors. Dizal (Jiangsu) Pharmaceutical Co., Ltd. was founded in 2017 and is based in Shanghai, China.
More stocks
- Camurus AB (CAMX.ST)
- WSFS FINANCIAL CORP (WSFS)
- SATS Ltd (S58.SI)
- Jumbo SA (BELA.AT)
- Sportradar Group AG (SRAD)
- Dorman Products, Inc. (DORM)
- Boot Barn Holdings, Inc. (BOOT)
- JPMorgan Global Growth & Income PLC (JGGI.L)
- MARRIOTT VACATIONS WORLDWIDE Corp (VAC)
- Titan SA (TITC.BR)
- RENK Group (R3NK.DE)
- Sinomach Precision Industry Co Ltd (002046.SZ)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.